로딩 중…
지수 로딩 중…
Stoke Therapeutics, Inc.
STOK· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$29.56+2.43%
2026-08-03
Financials
Valuation Metrics
Stoke Therapeutics, Inc.'s Market Cap is $1.84B. At end of 2025 it was $1.85B. Ranked #2113 of 3,112 in US market (top 68%), #817 of 1,445 on NASDAQ (top 57%), #145 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.84B | US#2,113/3,112 Sec#145/269 |
| Revenue | $32M | US#2,890/3,112 Sec#167/269 |
| Net Income | $-170M | US—/3,112 Sec—/269 |
| Total Assets | $443M | US#2,790/3,112 Sec#171/269 |
| Net Assets | $395M | US#2,413/3,112 Sec#134/269 |
| Value | ||
| P/B | 4.66x | US#2,111/3,112 Sec#134/269 |
| P/S | 57.39x | US#2,885/3,112 Sec#171/269 |
| FCF Yield | -8.02% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -42.99% | US#2,706/3,112 Sec#159/269 |
| ROA | -38.30% | US#2,921/3,112 Sec#188/269 |
| Op. Margin | -577.46% | US#2,902/3,112 Sec#166/269 |
| Revenue Growth | -96.07% | US#2,939/3,112 Sec#185/269 |
| Earnings Growth | -144.30% | US#2,163/3,112 Sec#71/269 |
| Financial Health | ||
| Debt Ratio | 12.26% | US#139/3,112 Sec#60/269 |
| Total Debt | $3M | US#2,882/3,112 Sec#227/269 |
| FCF | $-148M | US#2,675/3,112 Sec#187/269 |
| Cash | $156M | US#1,918/3,112 Sec#145/269 |
| Current Ratio | 8.99x | US#276/3,112 Sec#88/269 |
| Performance | ||
| 1Y Return | 128.97% | US#212/3,112 Sec#61/269 |
| 1M Return | -9.60% | US#2,575/3,112 Sec#163/269 |
| From 52W High | -26.50% | US#2,014/3,112 Sec#144/269 |
| 1Y MDD | -37.16% | US#1,814/3,112 Sec#131/269 |
| Trading | ||
| Volume | 576,700 shares | US#1,954/3,112 Sec#192/269 |
| Trading Value | $17M | US#2,070/3,112 Sec#159/269 |
| Per Share | ||
| EPS | $-0.12 | US—/3,112 Sec—/269 |
| BPS | $6.04 | US#2,126/3,112 Sec#115/269 |